Satish Jindal

Fundador en

Antolrx, Inc.

Health Technology

Commercial Services

Finance

Perfil

Satish Jindal was the founder of Verastem, Inc. founded in 2010, where the title held was Head-Development in 2011.
Dr. Jindal is the founder of AnTolRx, Inc. founded in 2015, holding the title of Director since 2015.
Dr. Jindal is also the founder of NeoGenesis Pharmaceuticals, Inc.,Elicio Therapeutics, Inc. (United States)..
Dr. Jindal currently holds the positions of Chairman & Manager at Koutif Therapeutics LLC, Director at Aleta Biotherapeutics, Inc. since 2024, and General Partner at Advent Venture Partners LLP since 2022.
Former positions include Chief Executive Officer at Allied-Bristol Life Sciences LLC, Senior Director-Drug Discovery Group at PerSeptive Biosystems, Inc., Principal at Massachusetts Institute of Technology, Head-Research & Development at UCB Pharma, Inc., and Vice President at Schering-Plough Research Institute.
Education includes a doctorate degree conferred in 1992 from Panjab University Chandigarh.

Cargos activos de Satish Jindal

Empresas	Cargo	Inicio
Antolrx, Inc. Antolrx, Inc. BiotechnologyHealth Technology Operates in the healthcare industry focusing on biotechnology business	Fundador	01/01/2015
Koutif Therapeutics LLC Koutif Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapeutics	Presidente	-
Advent Venture Partners LLP Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners invests in middle market companies located in the United Kingdom, Europe and the United States. The firm focuses on life sciences such as new drug discovery across all modalities, med tech, enabling technologies and vaccines. It participates in seed and early stage capital requirements.	Inversor de Capital Privado	01/01/2022
Aleta Biotherapeutics, Inc. Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops cell therapy solutions for cancers and transforms cellular therapeutics to allow a broader spectrum of cancer indications	Director/Miembro de la Junta	01/01/2024

Todos los cargos activos de Satish Jindal

Antiguos cargos conocidos de Satish Jindal.

Empresas	Cargo	Fin
Elicio Therapeutics, Inc. (United States) Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases	Fundador	-
PerSeptive Biosystems, Inc. PerSeptive Biosystems, Inc. Medical SpecialtiesHealth Technology Makes and markets products and systems for the analysis, purification and synthesis of biomolecules	Corporate Officer/Principal	-
Allied-Bristol Life Sciences LLC Allied-Bristol Life Sciences LLC BiotechnologyHealth Technology Develops biopharmaceutical innovations	Director Ejecutivo	-
UCB Pharma, Inc. UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research, development & commercialisation of pharmeceutical and biotechnology products	Director Técnico/Científico/I+D	-
Massachusetts Institute of Technology Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Satish Jindal.

Formación de Satish Jindal.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Satish Jindal.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	13
PerSeptive Biosystems, Inc. PerSeptive Biosystems, Inc. Medical SpecialtiesHealth Technology Makes and markets products and systems for the analysis, purification and synthesis of biomolecules	Health Technology
NeoGenesis Pharmaceuticals, Inc. NeoGenesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Used to discover and develop small molecule drugs	Health Technology
Advent Venture Partners LLP Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners invests in middle market companies located in the United Kingdom, Europe and the United States. The firm focuses on life sciences such as new drug discovery across all modalities, med tech, enabling technologies and vaccines. It participates in seed and early stage capital requirements.	Finance
Elicio Therapeutics, Inc. (United States) Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases	Health Technology
Massachusetts Institute of Technology Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University	Finance
UCB Pharma, Inc. UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research, development & commercialisation of pharmeceutical and biotechnology products	Commercial Services
Panjab University Chandigarh Panjab University Chandigarh Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Schering-Plough Research Institute Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research	Health Technology
Verastem, Inc. Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs	Health Technology
Allied-Bristol Life Sciences LLC Allied-Bristol Life Sciences LLC BiotechnologyHealth Technology Develops biopharmaceutical innovations	Health Technology
Antolrx, Inc. Antolrx, Inc. BiotechnologyHealth Technology Operates in the healthcare industry focusing on biotechnology business	Health Technology
Koutif Therapeutics LLC Koutif Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapeutics	Commercial Services
Aleta Biotherapeutics, Inc. Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops cell therapy solutions for cancers and transforms cellular therapeutics to allow a broader spectrum of cancer indications	Commercial Services